Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hypertension
Biotech
AstraZeneca’s $1.3B hypertension med bet pays off with ph. 3 win
AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based on a phase 3 readout.
James Waldron
Jul 14, 2025 4:09am
Medtronic treats first patient in multi-organ denervation study
Jul 9, 2025 11:45am
Mineralys drug lowers blood pressure in yet another clinical win
Jun 17, 2025 9:25am
Large trial reveals link between lowered BP and dementia risk
Apr 24, 2025 11:33am
Mineralys stock jumps as hypertension drug posts double wins
Mar 10, 2025 9:13am
Boston Scientific snags renal denervation developer SoniVie
Mar 3, 2025 11:15am
